Cyclerion Therapeutics, Inc.

Symbol: CYCN




Market price today

  • -1.4832

    P/E Ratio

  • 0.0000

    PEG Ratio

  • 8.26M

    MRK Cap

  • 0.00%

    DIV Yield

Cyclerion Therapeutics, Inc. (CYCN) Stock Price & Analysis

Shares Outstanding


Gross Profit Margin


Operating Profit Margin


Net Profit Margin


Return on Assets


Return on Equity


Return on Capital Employed


Company general description and statistics

Sector: Healthcare
Industry: Biotechnology
CEO:Dr. Regina Graul Ph.D.
Full-time employees:1
Address:245 First Street

Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also developing Praliciguat, an orally administered systemic sGC stimulator, which is in Phase II studies to treat resistant hypertension and diabetic nephropathy; Olinciguat, an orally administered vascular sGC stimulator that is in Phase II studies for the sickle cell disease; and CY3018 for the treatment of disorders of the CNS. It has license agreement with Akebia Therapeutics, Inc. for the development, manufacture, medical affairs, and commercialization of pharmaceutical products, including pharmaceutical compound, and other related products and forms. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

General Outlook

In simple terms, Cyclerion Therapeutics, Inc. has 2.71 M shares that people are buying and selling right now.

Return on Investments

The company's asset efficiency, represented by a robust -0.380% return, is a testament to Cyclerion Therapeutics, Inc.'s adeptness in optimizing resource deployment. Cyclerion Therapeutics, Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -0.612%. Furthermore, the proficiency of Cyclerion Therapeutics, Inc. in capital utilization is underscored by a remarkable -1.692% return on capital employed.

Stock Prices

Cyclerion Therapeutics, Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $3.32, while its low point bottomed out at $3.07. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Cyclerion Therapeutics, Inc.'s stock market.

Liquidity Ratios

Analyzing CYCN liquidity ratios reveals its financial health of the firm. The current ratio of 384.66% gauges short-term asset coverage for liabilities. The quick ratio (362.94%) assesses immediate liquidity, while the cash ratio (362.94%) indicates cash reserves.

Current Ratio384.66%
Quick Ratio362.94%
Cash Ratio362.94%

Profitability Ratios

The effective tax rate stands at 91.06%, revealing its tax efficiency. The net income per EBT, 27.15%, and the EBT per EBIT, 98.13%, provide insights into its earnings hierarchy.

Effective Tax Rate91.06%
Net Income per EBT27.15%
EBT per EBIT98.13%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 3.85, it details the span from stock purchase to revenue. The 4 days it takes to settle debts showcases its creditor relations.

Days of Sales Outstanding363

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, -8.59, and free cash flow per share, -8.59, depict cash generation on a per-share basis. The cash per share value, 3.06, showcases liquidity position.

Operating Cash Flow per Share-8.59
Free Cash Flow per Share-8.59
Cash per Share3.06
Free Cash Flow to Operating Cash Flow Ratio1.00

Debt and Leverage Ratios

An interest coverage of -216.99 indicates its ability to manage interest expenses.

Interest Coverage-216.99
Company Equity Multiplier1.18

Per Share Data

Net income per share, -8.99, reflects the portion of profit attributed to each share. The book value per share, 4.83, represents the net asset value distributed per share, while the tangible book value per share, 4.83, excludes intangible assets.

Net Income Per Share-8.99
Book Value Per Share4.83
Tangible Book Value Per Share4.83
Shareholders Equity Per Share4.83

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, -100.00%, indicates top-line expansion, while the gross profit growth, -100.00%, reveals profitability trends. EBIT growth, 78.26%, and operating income growth, 78.26%, offer insights into operational profitability progression. The net income growth, 52.00%, showcases bottom-line expansion, and the EPS growth, 55.38%, measures the growth in earnings per share.

Revenue Growth-100.00%
Gross Profit Growth-100.00%
EBIT Growth78.26%
Operating Income Growth78.26%
Net Income Growth52.00%
EPS Growth55.38%
EPS Diluted Growth55.38%
Weighted Average Shares Growth7.59%
Weighted Average Shares Diluted Growth7.59%
Operating Cash Flow Growth47.69%
Free Cash Flow Growth47.69%
3-Year Revenue Growth per Share-100.00%
10-Year Operating CF Growth per Share84.73%
5-Year Operating CF Growth per Share87.28%
3-Year Operating CF Growth per Share80.94%
10-Year Net Income Growth per Share86.93%
5-Year Net Income Growth per Share89.35%
3-Year Net Income Growth per Share81.20%
10-Year Shareholders Equity Growth per Share176.94%
5-Year Shareholders Equity Growth per Share163.11%
3-Year Shareholders Equity Growth per Share-87.66%
Receivables Growth-100.00%
Inventory Growth-100.00%
Asset Growth-26.02%
Book Value per Share Growth0.38%
R&D Expense Growth-95.19%
SGA Expenses Growth-43.93%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 261,300, captures the company's total value, considering both debt and equity. Income quality, 4.04, assesses the reliability of reported earnings.

Enterprise Value261,300
Income Quality4.04
Graham Number31.25
Return on Tangible Assets-157.13%
Graham Net Net2.35
Working Capital5,938,000
Tangible Asset Value11,288,000
Net Current Asset Value5,938,000
Average Receivables48,000
Average Payables2,084,000
Average Inventory402,500

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 0.67, and the price to book ratio, 0.67, reflect the market's valuation relative to the company's book value. Ratios like price to free cash flows, -0.39, and price to operating cash flows, -0.36, gauge market valuation against cash flow metrics.

Price Book Value Ratio0.67
Price to Book Ratio0.67
Price Cash Flow Ratio-0.36
Enterprise Value Multiple-1.27
Price Fair Value0.67
Price to Operating Cash Flow Ratio-0.36
Price to Free Cash Flows Ratio-0.39
Price to Tangible Book Ratio0.69
Enterprise Value Over EBITDA-0.03
EV to Operating Cash Flow-0.01
Earnings Yield-268.31%
Free Cash Flow Yield-271.25%
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Cyclerion Therapeutics, Inc. (CYCN) on the NASDAQ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -1.483 in 2024.

What is the ticker symbol of Cyclerion Therapeutics, Inc. stock?

The ticker symbol of Cyclerion Therapeutics, Inc. stock is CYCN.

What is company IPO date?

IPO date of Cyclerion Therapeutics, Inc. is 2019-03-18.

What is company current share price?

Current share price is 3.050 USD.

What is stock market cap today?

The market cap of stock today is 8264721.000.

What is PEG ratio in 2024?

The current 0.000 is 0.000 in 2024.

What is the number of employees in 2024?

In 2024 the company has 1.